Pharma executives emphasise that without urgent action, Europe may face a decline and an acceleration in the departure of ...

Global Data has revealed that the Top 20 Global Biopharmaceutical Companies have witnessed a 6 % growth in market ...

We recently published a list of 10 Best Multibagger Stocks to Buy According to Billionaires. In this article, we are going to ...

"European price controls and austerity measures reduce the attractiveness of its markets," Novartis CEO Vas Narasimhan and ...

Swiss drugmaker Roche said it plans to invest $50 billion in the U.S., the latest in a string of large companies boosting ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

When Trump announced the tariffs on April 2, pharma and semiconductor sectors heaved a sigh of relief as they were skipped, ...

Trump has made use of tariffs a central plank of his administration's economic and national security policies, rolling out a series of aggressive levies against trading partners that economists ...

A string of pharmaceutical bosses attended a three-hour dinner at Donald Trump’s Mar-a-Lago resort in Florida in December.

In this backdrop, shares of pharma companies have taken a hit. Since 2 April close, shares of Biocon and Aurobindo have lost about 10% and 8.6% whereas the stock of Dr Reddy’s is down 4.9%.

The cardiac segment led with a 10.8% value growth ... In March 2025, the pharma market registered a 7.5% value growth, with companies like Sun Pharma, Torrent Pharma, Intas, and Zydus posting ...